Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 etrasimod study in moderately to severely active ulcerative colitis
NL-OMON55828Phase 3Active, not recruiting
- Sponsor
- Arena Pharmaceuticals, Inc.
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in autoimmune colitis comparing Etrasimod with Placebo (2 arms). Primary endpoints: Clinical remission at Week 12 and Clinical remission at Week 52. Started May 2019; status: active, not recruiting.
02
Drugs
etrasimod
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON55828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55828.